Literature DB >> 8575516

Differentiation of in vivo effects of AMPA and NMDA receptor ligands using drug discrimination methods and convulsant/anticonvulsant activity.

J Arnt1, C Sánchez, S M Lenz, U Madsen, P Krogsgaard-Larsen.   

Abstract

The discriminative stimulus properties of the AMPA ((RS)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid) receptor agonist ATPA ((RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propionic acid) and NMDA (N-methyl-D-aspartic acid) in rats have been characterized. It is suggested that the cues are mediated by separate mechanisms in the central nervous system. The ATPA cue is not mimicked by NMDA or an NMDA receptor agonist, and is inhibited by the AMPA receptor antagonist (R)-APPA ((R)-2-amino-3-(3-hydroxy-5-phenylisoxazol-4-yl)propionic acid) but not the AMPA receptor antagonist ATOA ((RS)-2-amino-3-(3-carboxymethoxy-5-tert-butylisoxazol-4-yl)propio nic acid) or the NMDA receptor antagonist CPP ((RS)-3-(2-carboxypiperazin-4-yl)propyl)phosphonic acid). The ATPA cue is not mimicked by AMPA which is believed not to penetrate the blood-brain barrier. In contrast, ATPA does not generalize to the NMDA cue, which is mimicked by some NMDA receptor agonists (tetrazol-5-yl-glycine and AMAA ((RS)-2-amino-2-(3-hydroxy-5-methylisoxazol-4-yl)acetic acid)) and is inhibited by the NMDA receptor antagonist CPP. Highly potent convulsant activity was demonstrated in mice with all AMPA and NMDA receptor agonists after intracerebroventricular (i.c.v.) injection, whereas weaker or no effects were found after subcutaneous (s.c.) or intravenous injection. Only (RS)-tetrazol-5-yl-glycine had a potent effect after s.c. administration. I.c.v. ATOA and CPP inhibited convulsions induced by i.c.v. injection of AMPA or NMDA, while (R)-APPA was ineffective. These results indicate that there are differences in the structure-activity relations in the drug discrimination and convulsant/anticonvulsant models, even when effects after i.c.v. and s.c. injection are taken into consideration. The convulsion models are rapid tests which can give an indication of central nervous system penetration, but are less pharmacologically specific with respect to differentiation between AMPA and NMDA ligands where cue models demonstrate clear differences in effects of ligands with selectivity for receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8575516     DOI: 10.1016/0014-2999(95)00422-h

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Evaluation of blood-brain barrier passage of a muscarine M1 agonist and a series of analogous tetrahydropyridines measured by in vivo microdialysis.

Authors:  H H Sveigaard; L Dalgaard
Journal:  Pharm Res       Date:  2000-01       Impact factor: 4.200

2.  Locomotor activity detects subunit-selective effects of agonists and decahydroisoquinoline antagonists at AMPA/kainic acid ionotropic glutamate receptors in adult rats.

Authors:  Michael F O'neill; Graham Sanger; Paul L Ornstein; David J Osborne; Sandra M Woodhouse
Journal:  Psychopharmacology (Berl)       Date:  2005-01-26       Impact factor: 4.530

3.  Glutamate is a positive autocrine signal for glucagon release.

Authors:  Over Cabrera; M Caroline Jacques-Silva; Stephan Speier; Shao-Nian Yang; Martin Köhler; Alberto Fachado; Elaine Vieira; Juleen R Zierath; Richard Kibbey; Dora M Berman; Norma S Kenyon; Camillo Ricordi; Alejandro Caicedo; Per-Olof Berggren
Journal:  Cell Metab       Date:  2008-06       Impact factor: 27.287

4.  Enzyme-luminescence method: Tool for real-time monitoring of natural neurotoxins in vitro and l-glutamate release from primary cortical neurons.

Authors:  S M Zakir Hossain
Journal:  Biotechnol Rep (Amst)       Date:  2016-01-18

5.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.